APHA:NSD-Tilray, Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 17.23

Change

0.00 (0.00)%

Market Cap

USD 6.86B

Volume

0.01B

Avg Analyst Target

USD 21.30 (+23.62%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Tilray Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The company offers cannabis-lifestyle and consumer packaged goods; and hemp-based foods and alcoholic beverages. It offers medical cannabis in extracts and dried flower forms; and cannabis extracts, including purified oil drops and capsules. The company supplies cannabis extract products to patients, physicians, pharmacies, hospitals, governments, and researchers. It has operations in Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company was formerly known as Aphria Inc. and changed its name to Tilray, Inc. Tilray Inc. is based in Leamington, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-20 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
TLRY Tilray Inc

-0.94 (-7.72%)

USD5.47B N/A N/A
CGC Canopy Growth Corporation

-1.19 (-8.09%)

USD5.33B N/A N/A
PCRX Pacira BioSciences Inc

-0.56 (-1.00%)

USD2.49B 14.52 23.27
ORGO Organogenesis Holdings Inc

-0.91 (-5.46%)

USD2.14B 29.75 23.24
CRON Cronos Group Inc

-0.26 (-4.27%)

USD2.13B 37.00 N/A
IRWD Ironwood Pharmaceuticals Inc

N/A

USD2.01B 3.94 9.52
DVAX Dynavax Technologies Corporati..

+0.08 (+0.54%)

USD1.72B N/A 86.33
SNDL Sundial Growers Inc

-0.04 (-5.68%)

USD1.49B -99,999.99 N/A

ETFs Containing APHA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 148.99% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 148.99% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 288.06% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 288.06% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 68.51% 92% A- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 68.51% 92% A- 88% B+
Risk Return Profile  
Volatility (Standard Deviation) 161.02% 10% F 9% F
Risk Adjusted Return 42.55% 85% B 54% F
Market Capitalization 6.86B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 60.60 N/A N/A N/A N/A
Price/Book Ratio 5.61 N/A N/A N/A N/A
Price / Cash Flow Ratio -51.30 N/A N/A N/A N/A
EV/EBITDA 454.68 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -34.14% N/A N/A N/A N/A
Return on Invested Capital -2.80% N/A N/A N/A N/A
Return on Assets -1.31% N/A N/A N/A N/A
Debt to Equity Ratio 22.09% N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.91 N/A N/A N/A N/A
Short Percent 8.53% N/A N/A N/A N/A
Beta 2.62 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.